Valuation: Alkermes plc

Market Cap 8.62B 7.53B 6.92B 6.45B 12.23B 821B 12.44B 83.28B 32.28B 403B 32.37B 31.66B 1,387B P/E 2026 *
-137x
P/E 2027 * 86.6x
Enterprise Value 9.58B 8.37B 7.69B 7.17B 13.59B 912B 13.82B 92.57B 35.87B 447B 35.98B 35.2B 1,542B EV / Sales 2026 *
5.29x
EV / Sales 2027 * 4.93x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+3.04%
1 week+0.93%
Current month+1.77%
1 month+29.04%
3 months+53.04%
6 months+88.68%
Current year+90.56%
1 week 50.96
Extreme 50.96
55.28
1 month 40.62
Extreme 40.62
55.28
Current year 27
Extreme 27
55.28
1 year 25.16
Extreme 25.165
55.28
3 years 22.01
Extreme 22.01
55.28
5 years 21.24
Extreme 21.24
55.28
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
06-12Sell

Director

-2,000 0.0012%
06-04Sell

Compliance Officer

-2,034 0.0012%
06-01Fiscal year

Chief Technology Officer

19,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+3.04%+0.93%+83.86%+74.88% 8.62B
+0.36%+5.10%+1.04%+6.65% 48.62B
-1.40%+3.74%+397.02%+588.93% 39.86B
+1.78%+11.19%+25.90%-6.23% 33.91B
+1.25%+7.57%+21.23%+63.78% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+0.25%+2.58% - - 16.63B
+2.80%+8.14%+72.46%+135.22% 15.52B
+0.99%+1.26%+13.98%+18.72% 13.63B
-1.64%+7.74%+14.99%-28.64% 13.41B
Average +0.91%+7.16%+71.79%+98.41% 24.73B
Weighted average by Cap. +0.70%+7.55%+87.01%+126.04%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.45B 1.36B 2.57B 172B 2.61B 17.5B 6.78B 84.58B 6.8B 6.65B 291B 1.89B 1.65B 1.52B 1.42B 2.68B 180B 2.73B 18.28B 7.08B 88.34B 7.1B 6.95B 304B
Net income -61.83M -54.03M -49.61M -46.27M -87.71M -5.89B -89.19M -597M -232M -2.89B -232M -227M -9.95B 108M 94.79M 87.05M 81.18M 154M 10.33B 156M 1.05B 406M 5.07B 407M 398M 17.45B
Net Debt 961M 840M 771M 719M 1.36B 91.51B 1.39B 9.29B 3.6B 44.89B 3.61B 3.53B 155B 702M 613M 563M 525M 995M 66.78B 1.01B 6.78B 2.63B 32.76B 2.63B 2.58B 113B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
02/07/26 $53.37 +3.19% 516,877
01/07/26 $51.72 -1.29% 1,638,365
30/06/26 $52.40 -0.26% 2,958,468
29/06/26 $52.53 -4.63% 2,940,864
26/06/26 $55.08 +4.26% 7,563,601
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
51.72USD
Average target price
50.19USD
Spread / Average Target
-2.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock